financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Maintains Buy Opinion On Shares Of Canada Goose; Raises Price Target
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Maintains Buy Opinion On Shares Of Canada Goose; Raises Price Target
Nov 11, 2025 9:10 AM

11:55 AM EST, 11/11/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month price target by CAD4 to CAD20, based on 18x our FY 26 EPS estimate and in line with the company's three-year average forward P/E multiple. This reflects our view of improving fundamentals and GOOS's positioning in luxury, as it caters to a high-income consumer continuing to show strength in the U.S. We maintain our FY 26 and FY 27 EPS estimates of CAD1.10 and CAD1.15, respectively. GOOS posted normalized FQ2 EPS of -CAD0.14 vs. CAD0.05, CAD0.03 below consensus estimates on revenues of CAD273M vs. CAD268M and $1M below estimates. By channel in FQ2, Direct-to-Consumer revenues increased 21.8% Y/Y to CAD127M, while Wholesale revenues declined 1.0% to CAD136M. FQ2 gross margin expanded 110 bps Y/Y to 62.4% due to a higher proportion of DTC revenue, which was partially offset by higher product costs and product mix. SG&A expense as a percentage of revenue expanded 830 bps Y/Y to 68.9% due to labor and training costs, with new store openings and increased marketing spend ahead of the fall/winter season.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Oct 14, 2025
12:20 PM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $340, applying a forward P/E of 15.5x, near the three-year historical average at 15.0x on normalized earnings. We keep our EPS estimates at...
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Oct 13, 2025
06:20 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We revised our target price to USD98 (up from USD86), which implies 19.3x our 2026 EPADS estimate, largely in line with its five-year historical forward P/E. On October 10, U.S....
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Oct 12, 2025
01:00 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price by $15 to $510, valuing Berkshire's class B shares at 23x our 2026 operating EPS estimate of $21.80, versus their three-year average forward multiple...
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Oct 14, 2025
11:05 AM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Q3 earnings and the announcement of the separation of Orthopedics, we raise our target to $220 from $166. This is based on 19.2x our 2026 EPS estimate and is...
Copyright 2023-2025 - www.financetom.com All Rights Reserved